Copyright
©The Author(s) 2022.
World J Clin Cases. Jul 6, 2022; 10(19): 6360-6369
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6360
Published online Jul 6, 2022. doi: 10.12998/wjcc.v10.i19.6360
Figure 1 Main routines of elimination of epidermal growth factor receptor-tyrosine kinase inhibitors.
A: 86% of gefitinib is metabolized by the liver and excreted via feces; B: 80%-90% of erlotinib is metabolized by the liver and excreted via feces; C: 85% of afatinib is metabolized by the liver and excreted via feces; D: 68% of osimertinib is metabolized by the liver and excreted via feces.
- Citation: Lan CC, Hsieh PC, Huang CY, Yang MC, Su WL, Wu CW, Wu YK. Review of epidermal growth factor receptor-tyrosine kinase inhibitors administration to non-small-cell lung cancer patients undergoing hemodialysis. World J Clin Cases 2022; 10(19): 6360-6369
- URL: https://www.wjgnet.com/2307-8960/full/v10/i19/6360.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i19.6360